Crinetics Pharmaceuticals Inc CRNX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if CRNX is a good fit for your portfolio.
News
-
EY Announces Scott Struthers, Ph.D., CEO and Founder of Crinetics Pharmaceuticals, as an Entrepreneur Of The Year® 2024 Pacific Southwest Award Winner
-
Crinetics Pharmaceuticals Announces June 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Crinetics Announces Positive Initial Findings at ENDO 2024 for Atumelnant in Two Ongoing, Open-Label Studies for the Treatment of Congenital Adrenal Hyperplasia (CAH) and ACTH-Dependent Cushing’s Syndrome (ADCS)
-
Crinetics Presents New Data at ENDO 2024 that Increases Body of Evidence Positioning Once-Daily, Oral Paltusotine as Potential First-Choice Treatment Option for Acromegaly
-
Crinetics Pharmaceuticals Appoints Robert M. Cuddihy, M.D., as Senior Vice President of Medical Affairs
-
Crinetics Pharmaceuticals Announces Early Release of ENDO 2024 Late-Breaking Abstracts
-
Crinetics Pharmaceuticals Announces May 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Crinetics Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update
Trading Information
- Previous Close Price
- $44.20
- Day Range
- $43.71–44.46
- 52-Week Range
- $15.76–53.70
- Bid/Ask
- $43.20 / $43.90
- Market Cap
- $3.46 Bil
- Volume/Avg
- 572,256 / 899,310
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 1,391.43
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Crinetics Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 210
- Website
- https://www.crinetics.com
Comparables
Valuation
|
Metric
|
CRNX
|
IMVT
|
SLRN
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 3.93 | 6.34 | 0.62 |
Price/Sales | 1,391.43 | — | — |
Price/Cash Flow | — | — | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
CRNX
|
IMVT
|
SLRN
|
|---|---|---|---|
Quick Ratio | 17.59 | 13.18 | 13.08 |
Current Ratio | 17.72 | 13.70 | 13.27 |
Interest Coverage | — | — | — |
Quick Ratio
CRNX
IMVT
SLRN
Profitability
|
Metric
|
CRNX
|
IMVT
|
SLRN
|
|---|---|---|---|
Return on Assets (Normalized) | −33.04% | −44.70% | −28.15% |
Return on Equity (Normalized) | −37.88% | −49.06% | −35.30% |
Return on Invested Capital (Normalized) | −39.10% | −53.44% | −41.97% |
Return on Assets
CRNX
IMVT
SLRN
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk A/S ADR
NVO
| Ncnxnnrdd | Hkf | $628.7 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Fbrgdpwg | Yztqmdt | $122.5 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Xnfzgrpv | Hybgcyd | $114.0 Bil | |||
| Moderna Inc
MRNA
| Zvldrgry | Vymn | $45.3 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Zjmvfyqw | Nnwppsh | $31.8 Bil | |||
| argenx SE ADR
ARGX
| Ssfpfrsx | Ffyq | $25.9 Bil | |||
| BioNTech SE ADR
BNTX
| Jtttsghd | Clvt | $19.3 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Tmbwwnft | Wsdhcy | $15.5 Bil | |||
| United Therapeutics Corp
UTHR
| Gvylzsxs | Cwm | $14.0 Bil | |||
| Royalty Pharma PLC Class A
RPRX
| Twtdhypddn | Mtqlt | $11.6 Bil |